Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide.

It had two arms (groups): one (experimental) and Diet-controlled (no intervention).

The registry classes the interventions as drug.

More on the Plan

Following baseline testing, participants begin tirzepatide vs diet. weight loss will be aggressive for the first six weeks with diet to match the tirzepatide weight loss that is expected.

After week 6 weight loss will occur naturally on both without matching.

The metabolic tests, regional fat scans, and biopsy will be repeated at week 6 and week 22.

Who Took Part

Enrollment: 66 planned participants were the target.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Pre and postmenopausal women will be eligible and details of last menstrual period and/or hormone replacement collected for statistical adjustment and formal testing for effect modification.

The full record lists 4 inclusion and 10 exclusion criteria; among the exclusions: prior bariatric surgery or liposuction; unstable body weight defined as self-reported weight change \>2 kg over the past 6 weeks; unstable hypertension (defined as bp \>160/100 mm hg).

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2023-11-09 with completion listed for 2028-06.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in Adipocyte Size (time frame: Baseline and Week 22). Change in Adipocyte Fat Storage Capacity (time frame: Baseline and Week 22). Assess changes in Regional Fat (time frame: Baseline, week 6, and week 22).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide in 66 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.